Other seborrheic dermatitis
Methodology & AI Transparency ⓘ
Other seborrheic dermatitis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Other seborrheic dermatitis—coded clinically as L21.8 across Skin & Dermatology guidelines—combines or targeted biologics [Other seborrheic dermatitis L21.8] with structured follow-up of Fasting Lipids & in Other seborrheic dermatitis (L21.8: ALT (if systemic) (Within baseline reference limits (L21.8)).
- 2 Real-world patient consensus: Diagnostic registry L21.8: Other seborrheic dermatitis is managed within Skin & Dermatology.
- 3 Typical cash cost range: Workup highlights for Other seborrheic dermatitis (L21.8): or targeted biologics [Other seborrheic dermatitis L21.8].
- 4 Top reported side effects / signs: Key Skin & Dermatology biomarkers for Other seborrheic dermatitis (L21.8): Affected Body Surface in Other seborrheic dermatitis (L21.8: Area (BSA /) & Fasting Lipids & in Other seborrheic dermatitis (L21.8: ALT (if systemic) (Within baseline reference limits (L21.8)).
Ask our AI Specialists anything about Other seborrheic dermatitis
What Is Other seborrheic dermatitis?
Other seborrheic dermatitis—coded clinically as L21.8 across Skin & Dermatology guidelines—combines or targeted biologics [Other seborrheic dermatitis L21.8] with structured follow-up of Fasting Lipids & in Other seborrheic dermatitis (L21.8: ALT (if systemic) (Within baseline reference limits (L21.8)).
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Other seborrheic dermatitis (L21.8, Skin & Dermatology) reflects cutaneous immune skewing in Other seborrheic dermatitis (L21.8: (Th2/IL-4/IL-13 in atopic). longitudinal control is benchmarked via Affected Body Surface in Other seborrheic dermatitis (L21.8: Area (BSA /).
Common Symptoms & Clinical Signs
- • Presentation of Other seborrheic dermatitis (L21.8): compromised epidermal barrier in Other seborrheic dermatitis (L21.8: with dryness, fissuring,)
- • Secondary Other seborrheic dermatitis clinical sign: post-inflammatory hyperpigmentation, facial in Other seborrheic dermatitis (L21.8: flushing, or pitted)
- • Symptom flares in Other seborrheic dermatitis correlating with Affected Body Surface in Other seborrheic dermatitis (L21.8: Area (BSA /) deviation outside Clear or Almost Clear (IGA 0–1) (L21.8)
- • Functional skin & dermatology impact requiring or targeted biologics [Other seborrheic dermatitis L21.8] evaluation (L21.8)
Other seborrheic dermatitis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L21.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Affected Body Surface in Other seborrheic dermatitis (L21.8: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L21.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Other seborrheic dermatitis (L21.8: ALT (if systemic) | Within baseline reference limits (L21.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Other seborrheic dermatitis (L21.8: & hs-CRP) | 25(OH)D 40–65 ng/mL (L21.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Other seborrheic dermatitis
Treatment selection for Other seborrheic dermatitis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Other seborrheic dermatitis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Valsartan vs. other angiotensin II receptor blockers in the treatment of high: What a 13,110-Participant Study Found Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential high blood pressure. International journal of clinical practice • 2009-05-15 • Meta-Analysis | N = 13,110 | 99/100 | PMID 19392925 ↗ |
| New Insights on Efficacy comparison of monotherapies and combination therapies for androgenetic: What a 3,133-Participant Study Found In recent years, combination therapies are showing significant promise as potential therapies. Dermatologic therapy • 2022-03-15 • Meta-Analysis | N = 3,133 | 99/100 | PMID 34897933 ↗ |
| New Insights on Combination Therapy in Androgenetic hair loss: A Network Meta-Analysis of: What a 3,012-Participant Study Found Based on the current studies, we found that the combination of Minoxidil with spironolactone, PRPF, flutamide, and finasteride may offer better treatment outcomes for patients with androgenetic hair loss. Aesthetic plastic surgery • 2026-07-15 • Meta-Analysis | N = 3,012 | 99/100 | PMID 42168420 ↗ |
| New Insights on Safety profile of telmisartan as single-drug treatment or combined with: What a 8,023-Participant Study Found The consolidated data show that telmisartan +/- HCTZ are well tolerated in patients of all ages and have placebo-like tolerabilities. Blood pressure. Supplement • 2008-06-15 • Randomized Controlled Trial | N = 8,023 | 96/100 | PMID 18705533 ↗ |
| New Insights on Telmisartan and amlodipine single-pill combinations vs amlodipine single-drug: What a 1,097-Participant Study Found Superior BP reductions were also seen with T40-T80/A5 vs A10, with BP goal rates at least as high as with A10; however, there was significantly more peripheral edema with A10 (27.2% vs 4.3% for pooled. Journal of clinical hypertension (Greenwich, Conn.) • 2011-07-15 • Randomized Controlled Trial | N = 1,097 | 96/100 | PMID 21762357 ↗ |
Other seborrheic dermatitis Patient Community & “People Like Me” Threads
Filter Other seborrheic dermatitis community threads and patient logs by age, biological sex, dosage, and treatment duration.